The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Epitranscriptomic Therapies Market From 2026 To 2030?

The epitranscriptomic therapies market has seen rapid expansion in recent years. Its valuation is anticipated to climb from $1.56 billion in 2025 to $1.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 21.6%. The historical growth in this sector can be attributed to several factors including progress in RNA biology research, a deeper insight into gene regulation mechanisms, the expansion of oncology research programs, the availability of cutting-edge sequencing technologies, and an increase in translational medicine initiatives.

The epitranscriptomic therapies market size is anticipated to experience substantial growth in the upcoming years, expanding to $4.2 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 21.9%. This projected growth is attributed to factors such as increasing investments in RNA-based therapeutics, a rising demand for targeted cancer treatments, the expansion of personalized medicine approaches, growing clinical trial activity within epitranscriptomics, and increasing regulatory engagement concerning novel RNA therapies. Prominent trends throughout this period include the increasing development of epitranscriptomic drug pipelines, the growing utilization of RNA modification profiling tools, the expansion of combination epitranscriptomic therapies, the rising integration of bioinformatics in therapy design, and an enhanced focus on precision medicine applications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33108&type=smp

What Key Growth Drivers Are Influencing The Epitranscriptomic Therapies Market?

The epitranscriptomic therapies market is projected to grow in the future due to the rising demand for personalized medicine. This medical approach involves customizing healthcare decisions, treatments, and interventions according to each patient’s unique characteristics, such as their genetic profile, lifestyle, and environment. The primary factor behind the increasing need for personalized medicine is the growing incidence of chronic and complex diseases, as customized treatments can more effectively address individual patient requirements and enhance outcomes. Personalized medicine assists epitranscriptomic therapies by tailoring treatments to an individual’s specific RNA modification patterns, thereby boosting therapeutic effectiveness while minimizing the risk of adverse effects. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. The personalized treatments newly approved in 2023 also included seven cancer drugs and three for other diseases and conditions. Therefore, the escalating demand for personalized medicine is a significant driver for the growth of the epitranscriptomic therapies market.

Which Segment Groups Define The Epitranscriptomic Therapies Market Landscape?

The epitranscriptomic therapies market covered in this report is segmented –

1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types

2) By Route of Administration: Injectable; Oral; Other Routes Of Administration

3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications

4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users

Subsegments:

1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors

2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes

3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides

4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies

What Trends Are Impacting The Epitranscriptomic Therapies Market?

Leading companies in the epitranscriptomic therapies market are prioritizing strategic alliances to develop innovative RNA-modifying cancer treatments. Strategic partnerships are collaborative arrangements where organizations combine resources, knowledge, or strengths to pursue shared objectives, leading to faster growth, reduced operational risks, and enhanced market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a UK-based biotechnology company, partnered with Alida Biosciences Inc., a US-based technology company, to advance cancer therapies targeting epitranscriptomic mechanisms. This collaboration focuses on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials of STC-15, a first-in-class METTL3 inhibitor. The partnership aims to identify and validate m6A RNA modification biomarkers that can predict patient responses and optimize therapeutic strategies. This joint effort combines drug development with advanced RNA profiling, representing a significant advancement in epitranscriptomic cancer therapies.

Which Companies Are Influencing The Epitranscriptomic Therapies Market?

Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.

Access The Complete Epitranscriptomic Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/epitranscriptomic-therapies-market-report

Which Region Has The Strongest Presence In The Epitranscriptomic Therapies Market?

North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Epitranscriptomic Therapies Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model